In advance of a meeting to assess the value of multiple myeloma treatments, Amgen is publicly questioning the extent to which the session will fairly evaluate the medicines.
The meeting comes as concerns mount over the cost of these medications. There are now 10 treatments available for multiple myeloma, which causes cancer cells to accumulate in the bone marrow, and three won regulatory approval last fall. But these medicines are also expensive, ranging from $8,000 to $14,000 a month.
